215 related articles for article (PubMed ID: 22517208)
1. Rituximab for noninfectious uveitis.
Miserocchi E; Modorati G
Dev Ophthalmol; 2012; 51():98-109. PubMed ID: 22517208
[TBL] [Abstract][Full Text] [Related]
2. Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases.
Miserocchi E; Pontikaki I; Modorati G; Gattinara M; Meroni PL; Gerloni V
Autoimmun Rev; 2011 Nov; 11(1):35-9. PubMed ID: 21763790
[TBL] [Abstract][Full Text] [Related]
3. Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab).
Heiligenhaus A; Miserocchi E; Heinz C; Gerloni V; Kotaniemi K
Rheumatology (Oxford); 2011 Aug; 50(8):1390-4. PubMed ID: 21378109
[TBL] [Abstract][Full Text] [Related]
4. Rituximab in the treatment of refractory scleritis in patients with granulomatosis with polyangiitis (Wegener's).
Recillas-Gispert C; Serna-Ojeda JC; Flores-Suárez LF
Graefes Arch Clin Exp Ophthalmol; 2015 Dec; 253(12):2279-84. PubMed ID: 26507398
[TBL] [Abstract][Full Text] [Related]
5. [The role of rituximab in the treatment of ANCA-associated systemic vasculitis].
Roccatello D; Vangelista A; Pani A
G Ital Nefrol; 2011; 28(5):474-88. PubMed ID: 22028261
[TBL] [Abstract][Full Text] [Related]
6. Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report.
Foster CS; Chang PY; Ahmed AR
Ophthalmology; 2010 May; 117(5):861-9. PubMed ID: 20045562
[TBL] [Abstract][Full Text] [Related]
7. Treatment of antineutrophil cytoplasmic antibody-associated vasculitis with rituximab.
Cartin-Ceba R; Fervenza FC; Specks U
Curr Opin Rheumatol; 2012 Jan; 24(1):15-23. PubMed ID: 22089095
[TBL] [Abstract][Full Text] [Related]
8. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.
Stasi R; Stipa E; Del Poeta G; Amadori S; Newland AC; Provan D
Rheumatology (Oxford); 2006 Nov; 45(11):1432-6. PubMed ID: 16632482
[TBL] [Abstract][Full Text] [Related]
9. Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations.
Holle JU; Dubrau C; Herlyn K; Heller M; Ambrosch P; Noelle B; Reinhold-Keller E; Gross WL
Ann Rheum Dis; 2012 Mar; 71(3):327-33. PubMed ID: 22021864
[TBL] [Abstract][Full Text] [Related]
10. [Rationale and clinical evidence for the use of rituximab in glomerular diseases].
Mani LY; Vogt B; Burnier M; Golshayan D
Rev Med Suisse; 2011 Apr; 7(290):819-24. PubMed ID: 21595313
[TBL] [Abstract][Full Text] [Related]
11. Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis.
Murphy CC; Ayliffe WH; Booth A; Makanjuola D; Andrews PA; Jayne D
Ophthalmology; 2004 Feb; 111(2):352-6. PubMed ID: 15019389
[TBL] [Abstract][Full Text] [Related]
12. Safety and effectiveness of rituximab in patients with rheumatoid arthritis following an inadequate response to 1 prior tumor necrosis factor inhibitor: the RESET Trial.
Haraoui B; Bokarewa M; Kallmeyer I; Bykerk VP;
J Rheumatol; 2011 Dec; 38(12):2548-56. PubMed ID: 21965646
[TBL] [Abstract][Full Text] [Related]
13. B-cell targeted therapy with rituximab for thyroid eye disease: closer to the clinic.
Shen S; Chan A; Sfikakis PP; Hsiu Ling AL; Detorakis ET; Boboridis KG; Mavrikakis I
Surv Ophthalmol; 2013; 58(3):252-65. PubMed ID: 23253433
[TBL] [Abstract][Full Text] [Related]
14. Potential utility of rituximab for Graves' orbitopathy.
Salvi M; Vannucchi G; Beck-Peccoz P
J Clin Endocrinol Metab; 2013 Nov; 98(11):4291-9. PubMed ID: 24009135
[TBL] [Abstract][Full Text] [Related]
15. Anti-CD20 treatment in primary Sjögren's syndrome.
Isaksen K; Jonsson R; Omdal R
Scand J Immunol; 2008 Dec; 68(6):554-64. PubMed ID: 19000095
[TBL] [Abstract][Full Text] [Related]
16. [Severe Wegener's granulomatosis successfully treated with rituximab].
Semenkova EN; Krivosheev OG; Novikov PI; Osipenko VI; Nosova NR; Parfenova SA; Nikiforova NV; Borodin OO
Ter Arkh; 2010; 82(6):53-5. PubMed ID: 20731113
[TBL] [Abstract][Full Text] [Related]
17. A review of the current use of rituximab in autoimmune diseases.
Gürcan HM; Keskin DB; Stern JN; Nitzberg MA; Shekhani H; Ahmed AR
Int Immunopharmacol; 2009 Jan; 9(1):10-25. PubMed ID: 19000786
[TBL] [Abstract][Full Text] [Related]
18. [B cell depletion therapy using anti-CD20 antibodies in rheumatoid arthritis].
Yukawa N; Mimori T
Clin Calcium; 2007 Apr; 17(4):569-76. PubMed ID: 17404487
[TBL] [Abstract][Full Text] [Related]
19. Anti-CD20 therapy of treatment-resistant Wegener's granulomatosis: favourable but temporary response.
Omdal R; Wildhagen K; Hansen T; Gunnarsson R; Kristoffersen G
Scand J Rheumatol; 2005; 34(3):229-32. PubMed ID: 16134730
[TBL] [Abstract][Full Text] [Related]
20. Rituximab: rescue therapy in life-threatening complications or refractory autoimmune diseases: a single center experience.
Braun-Moscovici Y; Butbul-Aviel Y; Guralnik L; Toledano K; Markovits D; Rozin A; Nahir MA; Balbir-Gurman A
Rheumatol Int; 2013 Jun; 33(6):1495-504. PubMed ID: 23239037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
